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Section B 
Short Answer Questions 
Total No of Marks for this section: 50 
This section should be answered in the Answer Booklet provided. 




What are clinical effects of insulin resistance on glucose production and uptake by the liver?  
(Marks: 3) 
Question 2 








What measures should be implemented to improve urine output with loop diuretics therapy?  
(Marks: 4) 
Question 5 
Which ACEI is recommended as an initial therapy for patients at risk for acute kidney injury? 
(Marks: 2) 
Question 6 
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Patients with chronic kidney disease who have nocturia, sodium retention, sodium and 
volume overload are at high risk to develop which pathological condition? 
(Marks: 2) 
Question 8 
Hyperkalemia develops when glomerular filtration rate falls below.........% of normal.  
(Marks: 1) 
Question 9 
How is called metabolic disorder triggered by rapid cell destruction, usually during 




Which sodium-potassium exchange resin is proposed for hyperkalemia treatment in CKD?  
(Marks: 2) 
Question 11 
According to the NYHA classification what does class III include?                 
(Marks: 3) 
Question 12 
What types of vaccines are preferred in patients with COPD? 
(Marks:2) 
Question 13 




Why dual-antiplatelet therapy beyond one year after coronary stenting with drug-eluting 
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Question 15 
Why are patients after coronary stenting with drug-eluting stents required to receive statins 




Why are patients diagnosed with acute coronary syndrome required to have loading doses 




What is the main cause of death after acute myocardial infarction? 
(Marks: 2) 
Question 18 
If PCI is not feasible for acute myocardial infarction, within which period of time is fibrinolytic 
therapy recommended as a therapeutic option?                                                                                       
(Marks: 3) 
Question 19 
What are the beneficial clinical effects of beta-blockers in the treatment of heart failure?                                                          
(Marks: 4) 
Question 20 
What is the mechanism of action of beta2-adrenergic agonist in the treatment of asthma?    
(Marks: 3)       
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